Tenaya Therapeutics
Update in progressTNYA (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Tenaya Therapeutics, Inc. is a clinical‑stage biotechnology company focused on heart disease therapies in the United States. Its lead programs are TN-201, a gene therapy for MYBPC3‑associated hypertrophic cardiomyopathy (Phase 1b/2); TN-401, a gene therapy for PKP2‑associated ARVC (Phase 1b/2); and TN-301, a small‑molecule HDAC6 inhibitor for HFpEF (Phase 1). It uses gene addition, editing, silencing, and cellular regeneration, and collaborates with Alnylam for cardiovascular targets. Founded 2016, based in South San Francisco, CA.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.15
- Governance
- 0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Faraz Ali M.B.A.
- Founded2016
- Employees70
- Websitewww.tenayatherapeutics.com
Identifiers
- ISINUS87990A1060
- FIGIBBG00FPMK2S3
- CUSIP87990A106
- CIK0001858848